GlassScriptPhysician profile
Colleen Simon
NPI 1972266252
$4,218.44
in general payments reported to CMS, 2019-2025
18 companies · $237 in 2025
The $237 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $66.32 · 2022: $858 · 2023: $3,057 · 2025: $237.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,246 · Education: $48.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,245.59 |
| Education | $48.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $880.81 | 2022-2023 | |
| Otsuka America Pharmaceutical, INC. | $551.49 | 2021-2023 | Rexulti, Abilify Maintena, Nuedexta |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $453.89 | 2022-2023 | Caplyta |
| Alkermes, INC. | $383.50 | 2021-2023 | Lybalvi, Aristada, Vivitrol |
| Axsome Therapeutics, INC. | $263.14 | 2023 | Auvelity, Sunosi |
| Neurocrine Biosciences, INC. | $252.17 | 2023-2025 | Ingrezza |
| Corium, LLC | $246.53 | 2022-2023 | Azstarys |
| Lilly USA, LLC | $234.45 | 2022-2025 | Zepbound |
| Janssen Pharmaceuticals, INC | $204.19 | 2022-2023 | Spravato |
| Almatica Pharma LLC | $122.21 | 2023 | Gralise |
| Tris Pharma INC | $103.21 | 2022-2023 | Dyanavel Xr |
| Neos Therapeutics, LP | $97.80 | 2023 | Adzenys Xr-Odt |
| Takeda Pharmaceuticals U.S.A., INC. | $97.02 | 2023 | Trintellix |
| Noven Therapeutics, LLC | $89.36 | 2023 | Xelstrym, Secuado |
| Idorsia Pharmaceuticals US INC | $68.87 | 2022-2023 | Quviviq |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $64.76 | 2023 | Aplenzin, Wellbutrin |
| Lundbeck LLC | $61.15 | 2022-2023 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $43.89 | 2023 | Austedo Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Colleen Simon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.